{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:54:44Z","timestamp":1791618884819,"version":"4.3.4"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Glucagon-like peptide-1 (GLP-1) is a 30-amino acid hormone secreted by L cells in the distal ileum, colon, and pancreatic \u03b1 cells, which participates in blood sugar regulation by promoting insulin release, reducing glucagon levels, delaying gastric emptying, increasing satiety, and reducing appetite. GLP-1 specifically binds to the glucagon-like peptide-1 receptor (GLP-1R) in the body, directly stimulating the secretion of insulin by pancreatic \u03b2-cells, promoting proliferation and differentiation, and inhibiting cell apoptosis, thereby exerting a glycemic lowering effect. The glycemic regulating effect of GLP-1 and its analogues has been well studied in human and murine models in the circumstance of many diseases. Recent studies found that GLP-1 is able to modulate innate immune response in a number of inflammatory diseases. In the present review, we summarize the research progression of GLP-1 and its analogues in immunomodulation and related signal pathways.<\/jats:p>","DOI":"10.3389\/fimmu.2022.997578","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:20:58Z","timestamp":1670458858000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":120,"title":["GLP-1 receptor agonist as a modulator of innate immunity"],"prefix":"10.3389","volume":"13","author":[{"given":"Jun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwen","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoquan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra","year":"2022","journal-title":"Rev Endocrine Metab Disord"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-73234-9_36","article-title":"Boosting GLP-1 by natural products","volume":"1328","author":"Yaribeygi","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00836-9","article-title":"GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis","volume":"43","author":"Chen","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"B6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12933-021-01417-0","article-title":"Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients","volume":"20","author":"Saraiva","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.31068","article-title":"Biological actions and therapeutic potential of the glucagon-like peptides","volume":"122","author":"Drucker","year":"2002","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01734","article-title":"Role of incretin axis in inflammatory bowel disease","volume":"8","author":"Duan","year":"2017","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.10.013","article-title":"Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K\/Akt pathway in keratinocytes","volume":"146","author":"Nagae","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan","year":"2011","journal-title":"Diabetologia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000478872","article-title":"GLP-1\/GLP-1R signaling in regulation of adipocyte differentiation and lipogenesis","volume":"42","author":"Chen","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/jci72434","article-title":"Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect","volume":"124","author":"Sisley","year":"2014","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00588.2012","article-title":"High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats","volume":"305","author":"Mul","year":"2013","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2008.04.018","article-title":"CNS GLP-1 regulation of peripheral glucose homeostasis","volume":"94","author":"Sandoval","year":"2008","journal-title":"Physiol Behav"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00113.2017","article-title":"The glucagon-like peptide-1 receptor in the ventromedial hypothalamus reduces short-term food intake in male mice by regulating nutrient sensor activity","volume":"313","author":"Burmeister","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101407","article-title":"Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation","volume":"55","author":"Costa","year":"2022","journal-title":"Mol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.21037\/atm-21-4162","article-title":"Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data","volume":"9","author":"Zhao","year":"2021","journal-title":"Ann Trans Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2021.724030","article-title":"Anatomical and functional characterization of central amygdala glucagon-like peptide 1 receptor expressing neurons","volume":"15","author":"Zeng","year":"2021","journal-title":"Front Behav Neurosci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: Beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14580","article-title":"Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the united kingdom","volume":"24","author":"Webb","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15521","article-title":"The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration","volume":"159","author":"Li","year":"2021","journal-title":"J Neurochem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.3390\/cells11162587","article-title":"Induced human regulatory T cells express the glucagon-like peptide-1 receptor","volume":"11","author":"Rode","year":"2022","journal-title":"Cells"},{"key":"B25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1530\/JOE-20-0608","article-title":"Decreased expression of the GLP-1 receptor after segmental artery injury in mice","volume":"248","author":"Bjornholm","year":"2021","journal-title":"J Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.772446","article-title":"Glucagon-like peptide-1 receptor regulates macrophage migration in monosodium urate-induced peritoneal inflammation","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1440","article-title":"Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model","volume":"63","author":"Richards","year":"2014","journal-title":"Diabetes"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-1137","article-title":"Exendin-4 modulates diabetes onset in nonobese diabetic mice","volume":"149","author":"Hadjiyanni","year":"2008","journal-title":"Endocrinology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.07.086","article-title":"Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation","volume":"425","author":"Shiraishi","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4330-3","article-title":"The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype","volume":"60","author":"Vinu\u00e9","year":"2017","journal-title":"Diabetologia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1159\/000485776","article-title":"Exendin-4 induces bone marrow stromal cells migration through bone marrow-derived macrophages polarization via PKA-STAT3 signaling pathway","volume":"44","author":"Wang","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.041418","article-title":"Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis","volume":"124","author":"Shah","year":"2011","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2337\/db10-1338","article-title":"Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice","volume":"60","author":"Shirakawa","year":"2011","journal-title":"Diabetes"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8843310","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide ameliorates the development of periodontitis","volume":"2020","author":"Sawada","year":"2020","journal-title":"J Diabetes Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.7347","article-title":"Glucagon-like peptide-1 modulates RAW264.7 macrophage polarization by interfering with the JNK\/STAT3 signaling pathway","volume":"17","author":"Wan","year":"2019","journal-title":"Exp Ther Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1643-x","article-title":"Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells","volume":"53","author":"Hadjiyanni","year":"2010","journal-title":"Diabetologia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2010.70","article-title":"Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice","volume":"89","author":"Liu","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5568159","article-title":"Effect of GLP-1\/GLP-1R on the polarization of macrophages in the occurrence and development of atherosclerosis","volume":"2021","author":"Yang","year":"2021","journal-title":"Mediators Inflamm"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12860","article-title":"Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation","volume":"47","author":"Mitchell","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.12932\/ap-290821-1217","article-title":"Invariant natural killer T (iNKT) cells response in human melioidosis","author":"Kamuthachad","year":"","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study","volume":"171","author":"Buysschaert","year":"2014","journal-title":"Br J Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2011.03506.x","article-title":"Epithelial barrier biology: good fences make good neighbours","volume":"135","author":"Moens","year":"2012","journal-title":"Immunology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2337\/db14-1577","article-title":"GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R","volume":"64","author":"Yusta","year":"2015","journal-title":"Diabetes"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.21.014","article-title":"The effect of probiotic supplementation on systemic inflammation in dialysis patients","volume":"41","author":"Choi","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"B45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/imr.12170","article-title":"Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation","volume":"259","author":"Smigiel","year":"2014","journal-title":"Immunol Rev"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1447.049","article-title":"Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency","volume":"1150","author":"Xue","year":"2008","journal-title":"Ann New York Acad Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1993","article-title":"Fate mapping of IL-17-producing T cells in inflammatory responses","volume":"12","author":"Hirota","year":"2011","journal-title":"Nat Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1415675112","article-title":"Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis","volume":"112","author":"Harbour","year":"2015","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.3390\/ijms20071584","article-title":"Dulaglutide modulates the development of tissue-infiltrating Th1\/Th17 cells and the pathogenicity of encephalitogenic Th1 cells in the central nervous system","volume":"20","author":"Chiou","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2017.05.013","article-title":"GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice","volume":"31","author":"Itoh","year":"2017","journal-title":"J Diabetes its Complications"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2019.10.008","article-title":"Glucagon-like peptide-1 receptor agonism improves nephrotoxic serum nephritis by inhibiting T-cell proliferation","volume":"190","author":"Moschovaki Filippidou","year":"2020","journal-title":"Am J Pathol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-002083","article-title":"Exploring the GLP-1-GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography","volume":"9","author":"Manell","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jot.2022.02.001","article-title":"Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: A new opportunity","volume":"32","author":"Meurot","year":"2022","journal-title":"J Orthop Translat"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.12.149","article-title":"Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway","volume":"510","author":"Li","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110523","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-\u03baB and MAPK pathways via GLP-1R","volume":"130","author":"Li","year":"2020","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2019.03.003","article-title":"Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF-\u03b1-mediated NF-\u03baB and MAPK pathway","volume":"13","author":"Ye","year":"2019","journal-title":"Obes Res Clin Pract"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2018.3509","article-title":"GLP\u22121R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK\/NF\u2212\u03baB signaling pathways in streptozotocin\u2212induced diabetic rats","volume":"41","author":"Ma","year":"2018","journal-title":"Int J Mol Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/prca.201600169","article-title":"GLP-1 analogue, exendin-4, modulates MAPKs activity but not the heat shock response in human HepG2 cells","volume":"12","author":"Madhu","year":"2018","journal-title":"Proteomics Clin Applications"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12063","article-title":"Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes","volume":"4","author":"He","year":"2013","journal-title":"J Diabetes Invest"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1139\/bcb-2021-0365","article-title":"Cardiovascular protective effects of GLP-1: a focus on the MAPK signaling pathway","volume":"100","author":"Zhao","year":"2021","journal-title":"Biochem Cell Biol = Biochim Biol Cellulaire"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-020-01551-3","article-title":"Exendin-4 reverses high glucose-induced endothelial progenitor cell dysfunction via SDF-1\u03b2\/CXCR7-AMPK\/p38-MAPK\/IL-6 axis","volume":"57","author":"Yang","year":"2020","journal-title":"Acta Diabetol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2018.11.007","article-title":"Exendin-4 improves behaviorial deficits via GLP-1\/GLP-1R signaling following partial hepatectomy","volume":"1706","author":"Zhou","year":"2019","journal-title":"Brain Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2021.107463","article-title":"GLP-1R activation ameliorated novel-object recognition memory dysfunction via regulating hippocampal AMPK\/NF-\u03baB pathway in neuropathic pain mice","volume":"182","author":"Zhang","year":"2021","journal-title":"Neurobiol Learn Memory"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.10.197","article-title":"GLP-1RA promotes brown adipogenesis of C3H10T1\/2 mesenchymal stem cells via the PI3K-AKT-mTOR signaling pathway","volume":"506","author":"Wang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.14348\/molcells.2018.2340","article-title":"Liraglutide inhibits the apoptosis of MC3T3-E1 cells induced by serum deprivation through cAMP\/PKA\/\u03b2-catenin and PI3K\/AKT\/GSK3\u03b2 signaling pathways","volume":"41","author":"Wu","year":"2018","journal-title":"Mol Cells"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0177-4","article-title":"Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1\/2 and PI3K\/Akt signaling pathways","volume":"14","author":"Shi","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2016.03.035","article-title":"Liraglutide protects cardiac microvascular endothelial cells against hypoxia\/reoxygenation injury through the suppression of the SR-Ca(2+)-XO-ROS axis via activation of the GLP-1R\/PI3K\/Akt\/survivin pathways","volume":"95","author":"Zhang","year":"2016","journal-title":"Free Radical Biol Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2017.09.018","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)\/protein kinase b (AKT), extracellular signal-related kinase (ERK)1\/2, and cAMP\/protein kinase a (PKA) signaling pathways involving \u03b2-catenin","volume":"360","author":"Wu","year":"2017","journal-title":"Exp Cell Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12291","article-title":"Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K\/Akt pathway","volume":"16","author":"Zhao","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.24425","article-title":"Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP\/PKA pathway","volume":"114","author":"Chang","year":"2013","journal-title":"J Cell Biochem"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.11909\/j.issn.1671-5411.2015.04.013","article-title":"Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in raw 264.7 cells involving the AMPK\/SREBP1 pathway","volume":"12","author":"Wang","year":"2015","journal-title":"J Geriatr Cardiol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2019.01.014","article-title":"GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK","volume":"107","author":"Yang","year":"2019","journal-title":"Exp Mol Pathol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2017.12.009","article-title":"Newer GLP-1 receptor agonists and obesity-diabetes","volume":"100","author":"Brown","year":"2018","journal-title":"Peptides"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00013.2014","article-title":"Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease","volume":"95","author":"Sandoval","year":"2015","journal-title":"Physiol Rev"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.735019","article-title":"Striking the balance: GLP-1\/Glucagon Co-agonism as a treatment strategy for obesity","volume":"12","author":"Hope","year":"2021","journal-title":"Front Endocrinol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105782","article-title":"Anti-diabetic drugs and weight loss in patients with type 2 diabetes","volume":"171","author":"Lazzaroni","year":"2021","journal-title":"Pharmacol Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2016.03.017","article-title":"Perspectives in GLP-1 research: New targets, new receptors","volume":"27","author":"Cantini","year":"2016","journal-title":"Trends Endocrinol Metabol: TEM"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-101794","article-title":"Vasodilator effect of glucagon: Receptorial crosstalk among glucagon, GLP-1, and receptor for glucagon and GLP-1","volume":"48","author":"S\u00e9lley","year":"2016","journal-title":"Hormone Metab Res = Hormon- und Stoffwechselforschung = Hormones Metabol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09669-7","article-title":"Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease","volume":"22","author":"Bakbak","year":"2021","journal-title":"Rev Endocrine Metab Disord"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2941","article-title":"The future of the GLP-1 receptor agonists","volume":"321","author":"Hirsch","year":"2019","journal-title":"Jama"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.S312527","article-title":"An overview of similarities and differences in metabolic actions and effects of central nervous system between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose Co-Transporter-2 inhibitors (SGLT-2is)","volume":"14","author":"Wen","year":"2021","journal-title":"Diabetes Metab Syndrome Obes Targets Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2021.1924707","article-title":"The pleiotropic of GLP-1\/GLP-1R axis in central nervous system diseases","volume":"3","author":"Zhang","year":"2021","journal-title":"Int J Neurosci"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1002\/jcp.29204","article-title":"Role of liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke","volume":"235","author":"He","year":"2020","journal-title":"J Cell Physiol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-019-06915-8","article-title":"Neuroprotection in rats following ischaemia-reperfusion injury by GLP-1 analogues-liraglutide and semaglutide","volume":"33","author":"Basalay","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.01112","article-title":"Glucagon-like peptide-1: A focus on neurodegenerative diseases","volume":"13","author":"Grieco","year":"2019","journal-title":"Front Neurosci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2004","article-title":"Do GLP-1-based therapies increase cancer risk","author":"Nauck","year":"2013","journal-title":"Diabetes Care"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1515-4","article-title":"Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas","volume":"53","author":"Nachnani","year":"2010","journal-title":"Diabetologia"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02055-z","article-title":"GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials","volume":"66","author":"Cao","year":"2019","journal-title":"Endocrine"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1038\/s41598-019-38956-2","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis","volume":"9","author":"Pinto","year":"2019","journal-title":"Sci Rep"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2965","article-title":"[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma","volume":"13","author":"Wicki","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1169","article-title":"Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth","volume":"63","author":"Nomiyama","year":"2014","journal-title":"Diabetes"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1210\/en.2017-00461","article-title":"Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-\u03baB activation","volume":"158","author":"Iwaya","year":"2017","journal-title":"Endocrinology"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1585-0","article-title":"The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells","volume":"132","author":"Ligumsky","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0366-6999.2012.08.018","article-title":"Rosuvastatin attenuates mucus secretion in a murine model of chronic asthma by inhibiting the gamma-aminobutyric acid type a receptor","volume":"125","author":"Zhu","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms160920195","article-title":"Glucagon like peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase a (PKA)-dependent nuclear factor-kappaB (NF-kappaB) signaling pathway in mice","volume":"16","author":"Zhu","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/all.14879","article-title":"Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice","volume":"76","author":"Toki","year":"2021","journal-title":"Allergy"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2021.102003","article-title":"Glucagon-like peptide 1 receptor (GLP-1R) agonist relieved asthmatic airway inflammation via suppression of NLRP3 inflammasome activation in obese asthma mice model","volume":"67","author":"Hur","year":"2021","journal-title":"Pulm Pharmacol Ther"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J Hepatol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial","volume":"33","author":"Lin","year":"2022","journal-title":"J Dermatol Treat"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.997578\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:21:03Z","timestamp":1670458863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.997578\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":103,"alternative-id":["10.3389\/fimmu.2022.997578"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.997578","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"article-number":"997578"}}